skip to Main Content

SynBioBeta 2022

April 12 – 14, 2022

Location: Oakland, CA

Breaking the Barrier to Long, High Purity Synthetic DNA

The use of synthetic biology is becoming established in a diverse range of high value, high growth markets. From food and agriculture to therapeutics, diagnostics, and vaccines; tools such as gene editing, DNA sequencing and gene synthesis are being used to build value-added products with advanced functionality (e.g., cell bioreactors, etc.) and desired end products (e.g., drugs, chemicals, etc.). The barrier to widespread implementation is the forty-year-old Phosphoramidite DNA synthesis chemistry that is limited to producing only short oligonucleotides.

Molecular Assemblies is developing a proprietary enzymatic chemistry and high-throughput platform that will break the barrier to producing long, high purity synthetic DNA. A key component of the chemistry is the development of engineered polymerases which are capable of efficient template-independent DNA synthesis. In collaboration with Molecular Assemblies, Codexis is leveraging its CodeEvolver® directed evolution platform to improve the efficiency and speed of nucleotide incorporation at elevated temperatures. Taken together, these advances will revolutionize the field of synthetic biology.


Matt Miller, Principal Scientist, Molecular & Cellular Engineering, Codexis

Bill Efcavitch, Co-founder and Chief Scientific Officer, Molecular Assemblies

Book a meeting on Swapcard
There are many steps to a healthier future.
Join us on our journey.

Schedule a meeting

Back To Top
Close search